المؤلفون: Lewis D. Turner (4600186), Chi H. Trinh (1316205), Ryan A. Hubball (11709864), Kyle M. Orritt (11709867), Chi-Chuan Lin (11709870), Julie E. Burns (11709873), Margaret A. Knowles (11709876), Colin W. G. Fishwick (7821107)

مصطلحات موضوعية: Biochemistry, Cell Biology, Pharmacology, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, subsequent iterative rounds, specific morphological differences, fgfr inhibitors currently, biological evaluation led, additional docking studies, guided approach toward, selective inhibitors exist, existing fragment series, exhibited moderate selectivity, de novo design, selective fgfr2 inhibitors, lead inhibitor resulted, selective fgfr2 inhibitor, yield compounds predicted, selective h, subtle changes, nanomolar potency, improve potency, development toward, complete loss, clinical trials

Relation: https://figshare.com/articles/journal_contribution/From_Fragment_to_Lead_De_Novo_Design_and_Development_toward_a_Selective_FGFR2_Inhibitor/17019711

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01163.s001

المؤلفون: Lewis D. Turner (4600186), Chi H. Trinh (1316205), Ryan A. Hubball (11709864), Kyle M. Orritt (11709867), Chi-Chuan Lin (11709870), Julie E. Burns (11709873), Margaret A. Knowles (11709876), Colin W. G. Fishwick (7821107)

مصطلحات موضوعية: Biochemistry, Cell Biology, Pharmacology, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, subsequent iterative rounds, specific morphological differences, fgfr inhibitors currently, biological evaluation led, additional docking studies, guided approach toward, selective inhibitors exist, existing fragment series, exhibited moderate selectivity, de novo design, selective fgfr2 inhibitors, lead inhibitor resulted, selective fgfr2 inhibitor, yield compounds predicted, selective h, subtle changes, nanomolar potency, improve potency, development toward, complete loss, clinical trials

Relation: https://figshare.com/articles/dataset/From_Fragment_to_Lead_De_Novo_Design_and_Development_toward_a_Selective_FGFR2_Inhibitor/17019714

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01163.s002